Xingnuan Li

Xingnuan Li


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2020 in Aging
Verified
Journal Article
Open access
TWTao Wang
Tao Wang
DZDonghuo Zhong
Donghuo Zhong
ZQZhongjun Qin
Zhongjun Qin
SHShan He
Shan He
YGYing Gong
Ying Gong
XLXingnuan Li
Xingnuan Li
MicroRNAs play an important role in the adipogenic differentiation of human bone marrow mesenchymal stem cells (hMSCs). How miR-100-3p influences such adipogenesis, however, remains uncertain. In this study, hMSC adipogenic differentiation was associated with miR-100-3p downregulation, and overexpressing this miRNA inhibited adipogenesis and the expression of adipogenic marker genes. Through bioinformatics approaches, miR-100-3p can bind the 3'-untranslated region (3'-UTR) of the mRNA encoding phosphoinositide 3-kinase regulatory subunit 1 (PIK3R1) such that miR-100-3p overexpression resulted in significant reductions in PIK3R1 expression. Importantly, overexpressing PIK3R1 was sufficient to reverse the anti-adipogenic effects of miR-100-3p overexpression. PIK3R1 is a critical component of the PI3K/AKT signaling pathway, and miR-100-3p overexpression resulted in reduced AKT phosphorylation in the context of adipogenesis. In addition, the adipogenic differentiation of hMSCs in which miR-100-3p was overexpressed was further enhanced upon treatment with the PI3K/AKT agonist 740Y-P relative to miR-100-3p overexpression alone. Taken together, these findings provide evidence that miR-100-3p inhibits the adipogenic differentiation of hMSCs by targeting PIK3R1 via the PI3K/AKT signaling pathway.

24 January 2026 in Biology
Verified
Journal Article
Open access
PDF file
GSGaojie Song
Gaojie Song
XLXingnuan Li
Xingnuan Li
JXJianjun Xiong
Jianjun Xiong
LCLingling Cheng
Lingling Cheng
Age-related osteoporosis is driven in part by senescence-associated rewiring of bone marrow mesenchymal stem cells (MSCs) from osteogenic toward adipogenic fates. Accumulating evidence indicates that epigenetic drift and reduced autophagy are not isolated lesions but are mechanistically coupled through a bidirectional DNA methylation and autophagy axis. Here, we summarize how promoter hypermethylation of genes involved in autophagy and osteogenesis suppresses autophagic flux and osteoblast lineage transcriptional programs. Conversely, autophagy insufficiency reshapes the methylome by limiting methyl donor availability, most notably S-adenosylmethionine (SAM), and by reducing the turnover of key epigenetic regulators, including DNA methyltransferases (DNMTs), ten-eleven translocation (TET) dioxygenases, and histone deacetylases (HDACs). This self-reinforcing circuitry exacerbates mitochondrial dysfunction, oxidative stress, and inflammation driven by the senescence-associated secretory phenotype (SASP), thereby stabilizing adipogenic bias and progressively impairing marrow niche homeostasis and bone remodeling. We further discuss therapeutic strategies to restore balance within this axis, including selective modulation of epigenetic enzymes; activation of AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin (mTOR) signaling with downstream engagement of Unc-51-like autophagy-activating kinase 1 (ULK1) and transcription factor EB (TFEB); targeting sirtuin pathways; mitochondria- and autophagy-supportive natural compounds; and bone-targeted delivery approaches or rational combination regimens.

26 August 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LHLongsheng Huang
Longsheng Huang
SHShan He
Shan He
TWTao Wang
Tao Wang
KLKai Long
Kai Long
BMBaicheng Ma
Baicheng Ma
XLXingnuan Li
Xingnuan Li
Circular RNAs (circRNAs) in controlling gene expression have been highlighted by increasing evidence, and their dysregulation has been linked to various diseases. However, the limited role of circRNAs in the adipogenesis of bone marrow-derived mesenchymal stem cells (BMSCs) has been explored. High-throughput sequencing of circRNA was carried out on BMSCs and AD induction 7d BMSCs. Then a substantial upregulation of circNDUFA13 was detected among circRNAs in AD induction 7d BMSCs. We found that the adipogenic differentiation of BMSCs was positively linked with circNDUFA13 expression levels. Adipogenesis in BMSCs was effectively inhibited by circNDUFA13 knockdown, whereas overexpression of circNDUFA13 promoted adipogenesis. It was noted that circNDUFA13 regulated the adipogenic differentiation of BMSCs by directly interacting with the signal transducer and activator of transcription 3 (STAT3), which activates CEBPβ transcription. The in vitro model also validated the in vivo findings. our results suggest that circNDUFA13 controlled the adipogenic differentiation of BMSCs by targeting STAT3 and CEBPβ activation.

31 August 2026 in Biology
Verified
Journal Article
Open access
PDF file
永王永彬 王
永彬 王
SHShan He
Shan He
HYHuan Yang
Huan Yang
JZJie Zhang
Jie Zhang
LYLikun Yu
Likun Yu
BMBaicheng Ma
Baicheng Ma
Type 1 diabetes mellitus is characterized by immune-mediated pancreatic β-cell loss and progressive impairment of insulin production. This study evaluated the effects of combined rituximab, a B-cell-directed therapy, and exendin-4, a glucagon-like peptide-1 receptor agonist, on β-cell-related function and metabolic outcomes in experimental type 1 diabetes. Pancreatic islets isolated from NOD-scid mice were used for in vitro assessment of viability, metabolic activity, insulin secretion under high-glucose conditions, and gene expression. Female NOD mice were assigned to control, exendin-4, rituximab, or combination treatment groups and treated for approximately 20 weeks. Combined treatment showed the greatest increases in insulin-related responses in vitro. In vivo, it was associated with more stable fasting blood glucose levels, improved oral glucose tolerance, delayed progression to hyperglycemia, increased circulating insulin and C-peptide levels, and reduced glucagon, HbA1c, and LDL levels. Histological and molecular analyses further demonstrated reduced pancreatic inflammatory damage, reduced apoptosis-associated changes, and increased BrdU- and cytokeratin-18-associated signals within insulin-positive islet regions. These findings support further investigation of combined B-cell-directed and β-cell-supportive strategies for preserving islet function and delaying disease progression in type 1 diabetes.

4 October 2025 in Stem Cell Reports
Verified
Journal Article
Open access
HLHaichun Liao
Haichun Liao
WLWen Li
Wen Li
LXLin Xu
Lin Xu
CZChao Zhao
Chao Zhao
XLXingnuan Li
Xingnuan Li
TWTao Wang
Tao Wang
The pathogenesis of osteoporosis is closely related to the impaired human bone marrow-derived stromal cells (hBMSCs) osteogenic differentiation. No studies to date, however, have established whether tRNA-derived fragments (tRFs) can influence osteogenic differentiation of hBMSCs or the onset of osteoporosis. Here, tRF-23 was found to control hBMSC osteogenesis through its ability to target suppressor of cytokine signaling 1 (SOCS1) via the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway. tRF-23 was then further established as a potential target for efforts to protect against bone loss and marrow adipose tissue (MAT) accumulation in osteoporotic model mice, and its molecular mechanism was also verified in vivo. Together, these results suggest a model in which tRF-23 can protect against bone loss induced by ovariectomized (OVX) through the augmentation of hBMSC osteogenesis, providing a foundation for characterizing the pathogenesis of osteoporosis and seeking new therapeutic targets for this disruptive condition.

8 July 2026 in Scientific Reports
Verified
Journal Article
Open access
XLXingnuan Li
Xingnuan Li
CZChao Zhang
Chao Zhang
XGXinhai Gui
Xinhai Gui
JWJiayu Wu
Jiayu Wu
YGYing Gong
Ying Gong
TWTao Wang
Tao Wang
Osteoporosis is a systemic skeletal disease associated with reduced bone density and impaired bone quality, which leading to a greater risk of fracture. The pathogenesis of osteoporosis is closely associated with compromised osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). The actin-cytoskeleton associated protein PALLADIN has been reported to play a central role in the remodeling of the actin-cytoskeleton. However, no studies to date have established whether PALLADIN can influence osteogenic differentiation of BMSCs or the onset of osteoporosis. Here, PALLADIN knockdown was observed to reduce osteogenic differentiation of BMSCs, confirming the involvement of the gene in osteoporosis. Knockdown also altered the cytoskeletal organization and reduced Ras homolog family member A (RhoA) activity to inhibit osteogenic differentiation. The results of the in vivo experiments showed that overexpression of Palladin reversed bone loss and marrow adipose tissue (MAT) accumulation in OVX mice, while Palladin knockdown increased both bone loss and MAT accumulation in OVX mice. Together, these results suggest a model in which Palladin protects against bone loss induced by OVX through the promotion of BMSCs osteogenesis. In human osteoporotic BMSCs, PALLADIN expression is significantly downregulated, correlating with disease status. While functional validation in primary human osteoporotic BMSCs remains to be performed, these preclinical findings establish Palladin as a novel regulator of BMSCs osteogenic differentiation and provide a foundation for future efforts to characterize the pathogenesis of osteoporosis and identify new therapeutic targets.